Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 8Terminated 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 3Thoracic 1Myeloid 1Genitourinary 1Gastrointestinal 1Dermatologic 1Classical hematology 1Breast 1

Conditions

Pancreatic Neoplasms 1

Interventions

Fluorouracil 51Oxaliplatin 49Gemcitabine 47Leucovorin 41Capecitabine 35Bevacizumab 29Irinotecan 25Cisplatin 22Radiotherapy 18Radiosurgery 18pembrolizumab 16Nivolumab 16Cetuximab 15Taxes 14Sorafenib 14Paclitaxel 13Biopsy 13Surgical Procedures, Operative 12Drug Therapy 11atezolizumab 10Radiation 10Albumin-Bound Paclitaxel 10lenvatinib 9durvalumab 9Magnetic Resonance Spectroscopy 9Folfox protocol 9Cyclophosphamide 9130-nm albumin-bound paclitaxel 9spartalizumab 8Chemotherapy, Adjuvant 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Flow Cytometry × Gastrointestinal × Clear all
NCT00524069 2013-02-01

Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery

Roswell Park Cancer Institute

Phase NA Withdrawn
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡